Ayodele Olusola Ilesanmi
Research Subjects
Ayodele Olusola Ilesanmi has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Noah Olabode Olaleke
Obafemi Awolowo University Teaching Hospital Complex, Ile-Ife, Nigeria
2 shared publications - Olalekan John Okesanya
Department of Medical Laboratory Science Neuropsychiatric Hospital, Aro Abeokuta Nigeria
2 shared publications - Pius Omoruyi Omosigho
Department of Medical Laboratory Science, Faculty of Applied Health Sciences, Edo State University, Uzairue, Nigeria
2 shared publications Akinleye Waheed A
1 shared publication- Arinze Favour Anyiam
Edo State University
1 shared publication Atanda Tiamiyu A
1 shared publication
Latest Publications
- Open Access
- 1 October 2024
- Published by Taylor & Francis in Adolescent Health, Medicine and Therapeutics
- Vol. ume 15, 83-91
Advancing Immunization in Africa: Overcoming Challenges to Achieve the 2030 Global Immunization Targets
African immunization programs are crucial in reducing the prevalence of infectious diseases and improving public health outcomes. This review provides an overview of the current status of immunization efforts in Africa, highlights key challenges, and offers recommendations to help the continent achieve the 2030 Global Immunization Goals. While progress has been made, significant challenges remain. For instance, the WHO African Region reports full immunization coverage at 56.5%, partial coverage at 35.1%, and zero immunization coverage at 8.4%. Between 2019 and 2021, approximately 67 million children in Africa did not receive routine vaccinations, with West and Central Africa particularly affected. DTP1 coverage remained stable at 80%, but DTP3 coverage saw a slight drop to 72% between 2021 and 2022. As of 2022, MCV1 coverage reached 69%, reflecting ongoing efforts against measles. Key barriers to vaccination include limited parental education, religious beliefs, inadequate healthcare systems, and vaccine hesitancy. Addressing these barriers requires community-driven approaches like door-to-door campaigns and mobile clinics. To reach the 2030 immunization targets, health systems must be strengthened, vaccine supply chains optimized, and financial resources—both domestic and international—expanded. The Immunization Agenda 2030 (IA2030) emphasizes data-driven decision-making, nation-ownership, and tailored strategies to overcome obstacles and raise immunization coverage among several demographic groups. Achieving these 2030 goals in Africa requires collaborative efforts to ensure equitable access to vaccines, address sociocultural challenges, and strengthen health system infrastructure.
- 1 October 2024
- Published by Taylor & Francis in Adolescent Health, Medicine and Therapeutics
- Vol. ume 15, 83-91
Open AccessAdvancing Immunization in Africa: Overcoming Challenges to Achieve the 2030 Global Immunization Targets
African immunization programs are crucial in reducing the prevalence of infectious diseases and improving public health outcomes. This review provides an overview of the current status of immunization efforts in Africa, highlights key challenges, and offers recommendations to help the continent achieve the 2030 Global Immunization Goals. While progress has been made, significant challenges remain. For instance, the WHO African Region reports full immunization coverage at 56.5%, partial coverage at 35.1%, and zero immunization coverage at 8.4%. Between 2019 and 2021, approximately 67 million children in Africa did not receive routine vaccinations, with West and Central Africa particularly affected. DTP1 coverage remained stable at 80%, but DTP3 coverage saw a slight drop to 72% between 2021 and 2022. As of 2022, MCV1 coverage reached 69%, reflecting ongoing efforts against measles. Key barriers to vaccination include limited parental education, religious beliefs, inadequate healthcare systems, and vaccine hesitancy. Addressing these barriers requires community-driven approaches like door-to-door campaigns and mobile clinics. To reach the 2030 immunization targets, health systems must be strengthened, vaccine supply chains optimized, and financial resources—both domestic and international—expanded. The Immunization Agenda 2030 (IA2030) emphasizes data-driven decision-making, nation-ownership, and tailored strategies to overcome obstacles and raise immunization coverage among several demographic groups. Achieving these 2030 goals in Africa requires collaborative efforts to ensure equitable access to vaccines, address sociocultural challenges, and strengthen health system infrastructure.
- 17 February 2024
- Published by Peertechz Publications Private Limited in Global Journal of Obesity, Diabetes and Metabolic Syndrome
- Vol. 11 (1) , 001-008
Low CD4+ T Cell count among HIV-seronegative Type 2 Diabetes Mellitus patients in Ilorin metropolis
Background and aims: Diabetes Mellitus (DM) is a metabolic disorder that manifests as chronic hyperglycemia accompanied by a dysfunctional metabolism of carbohydrates, lipids, and proteins. Several studies have earlier pointed out several complications associated with the disease and in particular, the sufferer’s susceptibility to various infectious diseases. We therefore sought to investigate the adaptive immune status of the condition, as represented by the assessment of CD4+ T cell count among DM patients. Method: Seventy-six type 2 DM patients were recruited for the study. Thirty (30) age and sex-matched, non-diabetic individuals were enrolled as negative controls. Their fasting blood sugar (FBS), HbA1c, and CD4 count were assayed using standardized procedures. The demographic and clinical data of the studied group and controls were compared with respect to age, sex, BMI, FBS, HbA1c, and CD4+ T cell counts. Result: The mean concentration of glucose (7.82 ± 2.58) and the percentage concentration of HBA1c (8.21 ± 2.31) were significantly higher in DM individuals as against the control (3.67 ± 0.66) (p = 0.0001) and (5.20 ± 0.48) (p = 0.0001) respectively. The CD4+ cell count was also significantly lower in DM subjects (843.58 ± 297.6) when compared with the control (1067.9 ±195.4) (p = 0.035). Conclusion: A significant reduction in CD4+ T cell level was noted among diabetic patients in our study, which could be a contributing factor for aggravating some of the associated complications in DM, especially those that involve susceptibility to infectious diseases. We found out that having Hb-AA is associated with normal or elevated CD4+ T cells in DM patients; whereas having the Hb-AS variant increases the chance of a low CD4+ T cell count. Assessment of CD4+ T cell count should be included as part of periodic investigations in DM patients, especially for those with unresolved complications, in spite of treatment.
- 17 February 2024
- Published by Peertechz Publications Private Limited in Global Journal of Obesity, Diabetes and Metabolic Syndrome
- Vol. 11 (1) , 001-008
Low CD4+ T Cell count among HIV-seronegative Type 2 Diabetes Mellitus patients in Ilorin metropolis
Background and aims: Diabetes Mellitus (DM) is a metabolic disorder that manifests as chronic hyperglycemia accompanied by a dysfunctional metabolism of carbohydrates, lipids, and proteins. Several studies have earlier pointed out several complications associated with the disease and in particular, the sufferer’s susceptibility to various infectious diseases. We therefore sought to investigate the adaptive immune status of the condition, as represented by the assessment of CD4+ T cell count among DM patients. Method: Seventy-six type 2 DM patients were recruited for the study. Thirty (30) age and sex-matched, non-diabetic individuals were enrolled as negative controls. Their fasting blood sugar (FBS), HbA1c, and CD4 count were assayed using standardized procedures. The demographic and clinical data of the studied group and controls were compared with respect to age, sex, BMI, FBS, HbA1c, and CD4+ T cell counts. Result: The mean concentration of glucose (7.82 ± 2.58) and the percentage concentration of HBA1c (8.21 ± 2.31) were significantly higher in DM individuals as against the control (3.67 ± 0.66) (p = 0.0001) and (5.20 ± 0.48) (p = 0.0001) respectively. The CD4+ cell count was also significantly lower in DM subjects (843.58 ± 297.6) when compared with the control (1067.9 ±195.4) (p = 0.035). Conclusion: A significant reduction in CD4+ T cell level was noted among diabetic patients in our study, which could be a contributing factor for aggravating some of the associated complications in DM, especially those that involve susceptibility to infectious diseases. We found out that having Hb-AA is associated with normal or elevated CD4+ T cells in DM patients; whereas having the Hb-AS variant increases the chance of a low CD4+ T cell count. Assessment of CD4+ T cell count should be included as part of periodic investigations in DM patients, especially for those with unresolved complications, in spite of treatment.
- Open Access
- 22 August 2023
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 11 (2) , 117-122
Effects of Methanolic Extract of Aloe vera on C-Reactive Protein and White Blood Cell Count of Wistar Rats With Inflammation
Background: It has been known for centuries that plants and plant-derived chemicals are useful in treating diseases, with Aloe vera being one of the biologically active plants. A significant role is played by the C-reactive protein (CRP) in many inflammatory conditions, while leukocytes play an integral role in the response of the immune system to infectious diseases. Objectives: This study explored the potential anti-inflammatory effects of Aloe vera methanolic extract on the total white blood cell (TWBC) count and CRP levels in Wistar rats received formalin. Methods: A total of 25 Wistar rats were divided into five groups (A to E), with group A serving as the control and the other groups receiving formalin to induce inflammation, followed by increasing doses of Aloe vera extract. The CRP level was measured using an enzyme-linked immunosorbent assay (ELISA) kit, and the TWBC count was determined using a Sysmex haematology autoanalyzer. Results: Research findings showed that 200 mg of Aloe vera methanolic extract effectively reduced the CRP level (0.056±0.0027) (P=0.04), while 600 mg of the extract significantly increased the TWBC count (13.920±4.757) (P=0.03). Conclusion: These findings suggest that Aloe vera extract may be an effective natural supplement for improving the immune system function and reducing inflammation in the body. However, further research is needed to fully understand the underlying mechanisms for these effects and to determine the optimal doses and potential side effects.
- 22 August 2023
- Published by Maad Rayan Publishing Company in Avicenna Journal of Medical Biochemistry
- Vol. 11 (2) , 117-122
Open AccessEffects of Methanolic Extract of Aloe vera on C-Reactive Protein and White Blood Cell Count of Wistar Rats With Inflammation
Background: It has been known for centuries that plants and plant-derived chemicals are useful in treating diseases, with Aloe vera being one of the biologically active plants. A significant role is played by the C-reactive protein (CRP) in many inflammatory conditions, while leukocytes play an integral role in the response of the immune system to infectious diseases. Objectives: This study explored the potential anti-inflammatory effects of Aloe vera methanolic extract on the total white blood cell (TWBC) count and CRP levels in Wistar rats received formalin. Methods: A total of 25 Wistar rats were divided into five groups (A to E), with group A serving as the control and the other groups receiving formalin to induce inflammation, followed by increasing doses of Aloe vera extract. The CRP level was measured using an enzyme-linked immunosorbent assay (ELISA) kit, and the TWBC count was determined using a Sysmex haematology autoanalyzer. Results: Research findings showed that 200 mg of Aloe vera methanolic extract effectively reduced the CRP level (0.056±0.0027) (P=0.04), while 600 mg of the extract significantly increased the TWBC count (13.920±4.757) (P=0.03). Conclusion: These findings suggest that Aloe vera extract may be an effective natural supplement for improving the immune system function and reducing inflammation in the body. However, further research is needed to fully understand the underlying mechanisms for these effects and to determine the optimal doses and potential side effects.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Global Health Science
- Vol. 5 (2)
Thrombocytopenia in HIV positive patients in Ilorin North-Central Local Government Area Kwara State, Nigeria
Omosigho PO, et al. J Glob Health Sci. 2023 Dec;5:e19. https://doi.org/10.35500/jghs.2023.5.e19
- 1 January 2023
- Published by XMLink in Journal of Global Health Science
- Vol. 5 (2)
Open AccessThrombocytopenia in HIV positive patients in Ilorin North-Central Local Government Area Kwara State, Nigeria
Omosigho PO, et al. J Glob Health Sci. 2023 Dec;5:e19. https://doi.org/10.35500/jghs.2023.5.e19